High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
275.00K
-5600%
-0.117
-51.19%
107.00K
-93.12%
-0.112
-25.33%
107.00K
-85.12%
-0.138
-1.43%
Estimates Revision
The market is revising Upward the revenue expectations for Atai Beckley N.V. (ATAI) for FY2025, with the revenue forecasts being adjusted by 33.86% over the past three months. During the same period, the stock price has changed by -3.72%.
Revenue Estimates for FY2025
Revise Upward
+33.86%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+32.83%
In Past 3 Month
Stock Price
Go Down
-3.72%
In Past 3 Month
8 Analyst Rating
Wall Street analysts forecast ATAI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATAI is 12.71 USD with a low forecast of 10.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.400
Low
10.00
Averages
12.71
High
16.00
Current: 4.400
Low
10.00
Averages
12.71
High
16.00
Berenberg
Positive -> Buy
upgrade
$12
2025-10-24
Reason
Berenberg
Price Target
$12
2025-10-24
upgrade
Positive -> Buy
Reason
Berenberg placed a Buy rating on Atai Life Sciences with a $12 price target saying the company has made "exceptional progress" since its initiation with a Positive rating six months ago. Atai has a building pipeline momentum, its funding is secured, Phase 3 entry for its lead programmed is due in the first half 2026, and several more catalysts are expected over the next 12 months, the analyst tells investors in a research note. Berenberg sees the stock's momentum continuing.
Canaccord
Buy
maintain
$11 -> $14
2025-10-22
Reason
Canaccord
Price Target
$11 -> $14
2025-10-22
maintain
Buy
Reason
Canaccord raised the firm's price target on Atai Life Sciences to $14 from $11 and keeps a Buy rating on the shares. The firm noted their merger with privatley held Beckley is on track to close in Q4 while recently announcing the FDA granted breakthrough therapy designation (BTD) to Beckley's BPL-003 (intranasal mebufotenin), which had solid Phase 2 data for treatment-resistant depression.
Jefferies
Buy
maintain
$7 -> $10
2025-10-17
Reason
Jefferies
Price Target
$7 -> $10
2025-10-17
maintain
Buy
Reason
Jefferies raised the firm's price target on Atai Life Sciences to $10 from $7 and keeps a Buy rating on the shares. The ATAI-Beckley story "becomes more attractive" with the FDA granting a breakthrough designation to BPL-003, according to the analyst, who expects Atai to meet with the FDA to discuss Phase 3 design and regulatory strategy in Q4. The firm, which views BPL-003 as differentiated from other psychedelics due to single-dose durability and an in-clinic dosing paradigm, notes that its analysis shows a 72%-plus approval rate for drugs with BTD, so it argues the drug's prospects "could be more favorable" than current Street thinking.
Oppenheimer
Oppenheimer
Outperform
maintain
$14 -> $16
2025-08-01
Reason
Oppenheimer
Oppenheimer
Price Target
$14 -> $16
2025-08-01
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on Atai Life Sciences to $16 from $14 and keeps an Outperform rating on the shares as recent dynamics bode well for BPL-003. As large cap players vie for leadership in neuroscience, psychiatry is increasingly in focus while acquisitions of smaller players are an important source of innovation, Oppenheimer notes.
H.C. Wainwright
Patrick Trucchio
Buy
maintain
$10 -> $15
2025-07-30
Reason
H.C. Wainwright
Patrick Trucchio
Price Target
$10 -> $15
2025-07-30
maintain
Buy
Reason
H.C. Wainwright analyst Patrick Trucchio raised the firm's price target on Atai Life Sciences to $15 from $10 and keeps a Buy rating on the shares. The firm remains bullish on Atai despite the Phase 2b trial evaluating inidascamine in patients with cognitive impairment associated with schizophrenia missing the primary endpoint. In a follow-up call, management reiterated the company focus on the company's wholly-owned psychedelics pipeline, including BPL-003, which has continued to exceed expectations, the analyst tells investors in a research note. H.C. Wainwright cites Atai's focus on its "most promising near-term asset" for the target increase.
Oppenheimer
Outperform
initiated
$14
2025-07-29
Reason
Oppenheimer
Price Target
$14
2025-07-29
initiated
Outperform
Reason
Oppenheimer initiated coverage of Atai Life Sciences with an Outperform rating and $14 price target. The firm says Atai is the leading the psychedelic revolution within neuropsychiatry. The market opportunity is underappreciated considering 10M patients could benefit from alternative approaches, the analyst tells investors in a research note. Atai's Phase 2b data for BPL-003 solidify a "transformational approach," the analyst tells investors in a research note.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Atai Beckley NV (ATAI.O) is -8.75, compared to its 5-year average forward P/E of -4.99. For a more detailed relative valuation and DCF analysis to assess Atai Beckley NV 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-4.99
Current PE
-8.75
Overvalued PE
-0.83
Undervalued PE
-9.14
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-3.80
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.50
Undervalued EV/EBITDA
-9.10
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
24003.49
Current PS
0.00
Overvalued PS
82558.57
Undervalued PS
-34551.59
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
Trading Trends
Insider
Insiders areBuying! The selling amount has increased 653.97% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 121.2% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areBuying! The selling amount has increased 653.97% over the last month.
Sold
Bought
ATAI News & Events
Events Timeline
(ET)
2025-11-12
07:10:44
Atai Beckley anticipates funding availability through 2029
2025-11-12
07:10:16
Atai Beckley announces Q3 earnings per share of 28 cents, surpassing consensus estimate of 12 cents.
2025-11-10 (ET)
2025-11-10
07:46:50
Atai Beckley reveals findings from Phase 2b OLE study of BPL-003
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/default_image/newsfilter.png)
Preview
5.0
11-20NewsfilterEnhanced Strengthens Executive Leadership Team and Board of Directors
Preview
1.0
11-13NewsfilterAtaiBeckley to Attend the Jefferies Global Healthcare Conference in London
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/6d6eb79f29649575059a72514a615df513914b55a815f5d33fe711ab7a52d549.png)
Preview
4.5
11-08MarketWatchTech Selloff Weakens Key S&P 500 Support — Here's When Stocks May Truly Decline
Sign Up For More News
People Also Watch
FAQ
What is Atai Beckley NV (ATAI) stock price today?
What is Atai Beckley NV (ATAI)'s business?
What is the price predicton of ATAI Stock?
What is Atai Beckley NV (ATAI)'s revenue for the last quarter?
What is Atai Beckley NV (ATAI)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Atai Beckley NV (ATAI)'s fundamentals?
How many employees does Atai Beckley NV (ATAI). have?